← All trials
NCT02503150
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 1, 2015
- Primary completion
- Dec 1, 2019
- Completion date
- Dec 1, 2020
- First posted
- —
- Last posted
- —
- Enrollment
- 480
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- People's Liberation Army of ChinaLead sponsor
- Chinese Academy of Medical SciencesOverall official - principal investigator
- Changhai HospitalCollaborator
- Fudan UniversityCollaborator
- First People's Hospital of HangzhouCollaborator
- Second Military Medical UniversityCollaborator
- Zhejiang UniversityCollaborator
- Haixin Biotechnology Co. LtdCollaborator
- Peking UniversityCollaborator
- People's Liberation Army of ChinaStudy director
- People's Liberation Army of ChinaStudy chair
- People's Liberation Army of ChinaCollaborator
- Jiao Tong UniversityCollaborator
- Chinese Academy of Medical SciencesCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.